Saturday, October 3, 2026

CBOE Volatility Index Bearish Momentum: 1.74% Down Since The Last Session

ViaNews Editorial Team

January 12, 2021

CBOE Volatility Index Bearish Momentum: 1.74% Down Since The Last Session

CBOE Volatility Index is currently on bearish momentum. At 10:27 EST on Tuesday, 12 January, CBOE Volatility Index is at $23.66, 1.74% down since the last session's close.

CBOE Volatility Index Range

CBOE Volatility Index is 1.851% up from its last session low of $23.23 and 4.635% down from its last session high of $24.81.

Over the last three sessions, CBOE Volatility Index's higher value was $24.81 and the lower value was $21.42.

Over the last seven sessions, CBOE Volatility Index's higher value was $29.19 and the lower value was $21.24.

Over the last month, CBOE Volatility Index's higher value was $31.46 and the lower value was $20.99.

Regarding CBOE Volatility Index's yearly highs and lows, it's 101.362% up from its 52-week low and 72.318% down from its 52-week high.

Volatility

CBOE Volatility Index's last day, last week, and last month's average volatility was a positive 11.69%, a negative 2.33%, and a positive 0.47%, respectively.

CBOE Volatility Index's last day, last week, and last month's high and low average amplitude percentage was 6.80%, 11.89%, and 11.00%, respectively.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com